Fusen Pharmaceutical Company Limited has scheduled a board meeting for 31 August 2026. Directors will review and approve the unaudited interim financial results for the six months ended 30 June 2026. The agenda also includes consideration of an interim dividend declaration. Chairman and Chief Executive Officer Cao Zhiming will preside over the session, joined by three other executive directors and three independent non-executive directors.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.